Current drug development for neurodegenerative diseases is limited by poor translation of preclinical animal models to clinical application in humans. This results in extremely costly late stage development failures and in companies dropping research activities for these diseases. With 53 million people affected by Alzheimer’s Disease (AD) and an expected rise to 106 million cases in 2050, there is a pressing demand for breakthroughs in treatments. Similar issues are seen for treatment of other neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS), Parkinson’s Disease (PD) and others.
InnoSer explores the use of advanced in-vitro brain models that make use of microtechnology. These models, or brain-on-a-chip (BOC) systems, can make use of healthy or patient-derived cells to study the phenotype, neuronal network formation and electrophysiological activity of these cells in a platform that allows for advanced read-out and a relevant, in vivo-like microenvironment. International partners from academia and industry have formed a team with InnoSer to further develop the current BOC technology for proof-of-concept purposes. Subsequently, InnoSer will further validate the proof-of-concept BOC system for use as an in vitro preclinical drug development platform.